“SynAct is at a significant inflection point with the company’s Phase 2b ADVANCE study in rheumatoid arthritis progressing well and multiple indications in the works to maximize the potential value of resomelagon,” said SynAct CEO Jeppe Øvlesen. “With Mads on board as part of our Copenhagen based team, we are strengthening our ability to develop and execute on our commercial and partnering opportunities. We are excited to have Mads on board.”

Mads Bjerregaard has held leading positions in life science companies during his more than 20 years of work experience including commercial and business development roles in Danish based biopharma and med-tech companies, Lundbeck, Zealand Pharma, and UNEEG Medical. Throughout his career, Mads has lived and worked internationally and has been pushing innovation towards commercialization in neurology, endocrinology, and gastroenterology. Mads holds a master’s degree from Copenhagen Business School.

CEO Jeppe Øvlesen continues, “I also want to thank Jim for his great support over the years, and I am grateful that he will continue to support SynAct from the advisory board going forward. He has incredible insight into the market and he will continue to support our efforts to maximize opportunities.”